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Abstract
Background: Previous population-based studies have found that delusional-like experiences (DLE) are prevalent in
the community, and are associated with a wide range of mental health disorders including substance use. The aim
of the study was to explore the association between DLE and three commonly used substances - tobacco, alcohol
and cannabis.
Methods: Subjects were drawn from the Australian National Survey of Mental Health and Wellbeing 2007. The
Composite International Diagnostic Interview was used to identify DLE, common psychiatric disorders, and
substance use. We examined the relationship between the variables of interest using logistic regression, adjusting
for potential confounding factors.
Results: Of 8 773 participants, 8.4% (n = 776) subjects endorsed one or more DLE. With respect to tobacco use,
compared to nonusers, DLE were more common in those who (a) had daily use, (b) commenced usage aged 15
years or less, and (c) those who smoked heavily (23 or more cigarettes per day). Participants with cannabis use
disorders were more likely to endorse DLE; this association was most prominent in those with an onset of 16 years
or younger. In contrast, the pattern of association between DLE versus alcohol use or dependence was less
consistent, however those with early onset alcohol use disorders were more likely to endorse DLE probe items.
Conclusions: While cannabis use disorders have been previously linked with DLE, our findings linking alcohol and
tobacco use and DLE suggest that the influence of these substances on psychosis-related outcomes warrants
closer scrutiny in longitudinal prospective studies.
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Background
In recent decades, there has been intense interest in the
links between cannabis use and psychosis [1,2]. Several
prospective population-based studies have found that
cannabis use is associated with an increased risk of
developing psychotic disorders later in life [3-8]. Among
those who have developed psychotic disorders, cannabis
use is associated with an earlier age of onset of such dis-
orders [9]. A growing body of evidence also shows that
cannabis use is associated with attenuated features of
psychoses, known as psychotic-like experiences (PLE) or
delusional-like experiences (DLE) [10-15]. In particular,
population-based studies in adolescents have reported
that early onset cannabis use is associated with a greater
likelihood of DLE endorsement [11,16,17].
Apart from cannabis, there has been less study of the
links between other substances and risk of psychosis or
DLE. Several prospective studies have reported that
tobacco smoking was associated with an increased risk
of later psychosis, and there was a dose-response rela-
tionship between the variables of interest [18-20]. With
respect to alcohol, one study found that younger age at
onset of alcohol dependence was associated with
increased risk of psychotic symptoms [21]. An Austra-
lian population-based study examined past-year associa-
tions between DLE, and the use of tobacco, cannabis
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any medium, provided the original work is properly cited.and alcohol [15]. This study found that regular tobacco,
alcohol and cannabis use disorders were much more
common in those who screened positive for psychotic
disorders (i.e. those who endorsed at least several CIDI
items related to psychotic symptoms).
The previous Australian study [15] was unable to
explore potential associations with age of onset of drug
use and DLE. We had the opportunity to address this
issue and explore the associations between DLE and
commonly used substances such as tobacco, alcohol and
cannabis. We were interested in exploring the associa-
tion between the variables of interest when adjusted for
a range of potential confounds. Based on the existing lit-
erature, we predicted that tobacco use, cannabis and
alcohol use disorders would be associated with endorse-
ment of DLE. We also predicted that those who
reported an earlier age of first use for these substances,
or those who had greater intake, would be more like to
endorse DLE compared to non-users.
Methods
Participants
Subjects were drawn from the Australian National Sur-
vey of Mental Health and Wellbeing 2007 (NSMHWB).
Details of the methodology have been published else-
where [22]. In brief, the NSMHWB was a national face-
to-face household survey of community residents aged
between 16 and 85 years. Sampling was based on ran-
dom selection from a stratified, multistage area probabil-
ity sample of private dwellings. Interviews were carried
out by trained interviewers from the Australian Bureau
of Statistics, a statutory body responsible for conducting
such surveys using ethical protocols that include written
informed consent. In total, 8,841 individuals participated
in the survey that represents an estimated population of
16 015 000 adults. As the response rate for this survey
was lower than expected (60%), extensive non-response
analyses were undertaken by the Australian Bureau of
Statistics in order to assess the reliability of the survey
estimates. As a result, adjustments were made to the
weighting strategy (full details available elsewhere http://
www.abs.gov.au[23]).
Assessment of DSM-IV diagnoses, delusional-like
experiences and physical disorders
A modified version of the World Mental Health Survey
Initiative of the Composite International Diagnostic
Interview (WMH-CIDI 3.0) was used to generate life-
time presence of DLEs, and DSM IV based diagnoses of
a wide range of common mental health disorders
including anxiety disorders, depressive disorders, and
alcohol or drug abuse or dependence.
For the assessment of DLEs, we used the items in Sec-
tion G designed to screen for possible psychosis. Details
of the DLEs are given in Table 1. Briefly, the DLE com-
ponent was composed of three ‘screen’ items followed
by three ‘probe’ items. Subjects who responded posi-
tively to any of the screen items, were administered the
‘probe’ items. The items covered the following features
of psychotic disorders: delusions of control, thought
interference and passivity (Question 1 and 1a); delusions
of reference and persecution (Question 2 and 2a); and
grandiose delusions (Question 3 and 3a). While endorse-
ment of screen items are more common, subsequent
endorsement of probe items is more likely to be predic-
tive of true psychotic features [24].
In order to keep a focus on isolated (subclinical) DLE,
and in order to allow comparisons with our previous
analyses based on this survey [25-28], individuals who
screened positively for schizophrenia (i.e. respondents
who reported ‘Yes’ to the item “Had been told at any
time by a psychiatrist that they had schizophrenia“)
were excluded from the analyses (n = 68), leaving a total
of 8 773 subjects for this study.
The WMH-CIDI instrument also includes checklists
related to the presence of physical disorders. Details of
the methodology have been published elsewhere [26].
Respondents were asked if they ever had any of six phy-
sical illnesses: (a) asthma, (b) gout, rheumatism or
arthritis, (c) cancers, (d) diabetes or high blood sugar
levels, (e) any heart attack, angina or high blood pres-
sure, and (f) stroke or effects of stroke.
Table 1 CIDI Screen and Probes items for Psychosis
(Delusional-like experiences, DLE)
Item G1 (PS1*):
Have you ever felt that your thoughts were being directly interfered
with or controlled by another person?
If yes, PS1A
#:
Did it come about in a way that many people would find hard to
believe, for instance, through telepathy?
Item G2 (PS2*):
Have you ever had a feeling that people were too interested in you?
If yes, PS2A
#:
Have you had a feeling that things were arranged so as to have a
special meaning for you, or even that harm might come to you?
Item G1 (PS3*):
Do you ever have any special powers that most people lack?
If yes, PS3A
#:
Do you belong to a group of people who also have these powers?
Item PS4
@:
Has a doctor ever told you that you may have schizophrenia?
*Screen items (lifetime) with answer (Yes/No): ‘Any screen’ items required ‘Yes’
answers to all three questions.
#Probe items (lifetime) with answer (Yes/No): ‘Any probe’ items required ‘Yes’
answers to PS1A and PS2A, and ‘No’ answer to PS3A.
@Sample excluded from the analyses (n = 68)
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Respondents were asked whether they used tobacco reg-
ularly ("current user”), and their age of starting use, and
current number of cigarettes or other tobacco products
used per day. All persons were assessed for alcohol, and
cannabis use disorders, based on DSM-IV diagnoses.
Details of DSM-IV diagnoses for alcohol use disorders
have been published elsewhere [29]. Briefly, in assessing
the presence of DSM-IV alcohol use disorders, partici-
pants were initially asked whether they had consumed at
least 12 alcohol drinks (containing 10 g of ethanol) in
any one year in their life-time. Respondents who
responded ‘yes’ were also asked whether they had ever
in their lifetime drank on > = 3 days a week and/or
have usually consumed > = 3 drinks on the days they
were drinking. Only those who answered this question
positively were administered the symptom questions
that operationalise the DSM-IV alcohol use/dependence
disorder diagnostic criteria. A series of 18 questions
operationalised the four alcohol use (major role, legal,
hazardous use, and social), and seven alcohol depen-
dence (tolerance, withdrawal, cutdown, larger, time
spent, give up and continued use) criteria.
Similar to the assessment of alcohol use disorder, the
2007 NSMHWB collected data on cannabis use disor-
ders. In assessing for a cannabis use disorder, subjects
were screened for any lifetime use - those who reported
lifetime use were then asked a series of five questions
for the diagnosis of use disorders, and 10 questions to
establish lifetime diagnosis of dependence.
Data analysis
For the main analyses, we examined the association
between reporting any DLE (i.e. at least one of the G
screen or probe items endorsed), and the tobacco, can-
nabis and alcohol related variables. For tobacco users,
respondents were asked about (a) age at first use, and
(b) current number of smokes per day. We divided
responses into quartiles (lowest quartile indicative of
earlier age of onset, or highest number of cigarettes use
respectively). ‘No smoking’ w a su s e da st h ereference
group for both variables. For cannabis and alcohol, ‘age
of onset of use disorder’ variables were also divided into
quartiles where ‘no onset’ w a su s e da st h ereference
group.
Based on previous research of factors associated with
DLE, in Model 1, we adjusted for sex and age of assess-
ment [30,31]. As previous studies have reported DLEs to
be associated with anxiety and depressive disorders [28],
and physical disorders [25] we examined a second
model adjusting for these potential confounding factors
together with other demographic variables including
marital status, migrant status, employment status and
educational status. As many individuals use more than
one substance [15], in Model 2 we also included adjust-
ment for exposure to ‘any other’ drug or alcohol abuse/
dependence (tobacco, alcohol, cannabis, opioid, stimu-
lant and sedatives).
The sample was weighted to adjust for differential
probabilities of selection within households, over-sam-
pling of population subgroups and non-response to
match census population distribution on a number of
geographic and socio-demographic variables [22]. The
initial weights were calibrated against known population
estimates. Replicate weight variables were developed
using the Jack-knife procedure of replication (i.e., the
analysis was repeated after one subject was dropped and
then the standard error was derived from the distribu-
tion of results from all ‘’minus one’’ resamples) [32].
Analyses were performed using Proc Surveylogistic [33]
which is designed to analyse complex survey sample
using SAS (version 9.2;Cary, NC: SAS Institute). Chi-
square tests for linear trend were used to assess dose-
response relationships between the exposure variables
and DLE.
Results
Of the full sample, 49.6% were male, 57.0% were either
married or in a de facto relationship, 32.2% had post-
school qualification, 65.2% were employed, and 62.9%
were born in Australia. Of the 8 773 subjects included
in the study, 776 (8.4%) positively endorsed one or more
DLE screen items (Table 2), and 295 (3.0%) endorsed
one or more probe items.
Association between tobacco use and DLE
About one-sixth (17.97%) of the population currently
used tobacco every day (Table 3). Compared to those
who did not use tobacco, individuals who smoked every-
day were significantly more likely to endorse both DLE
screen and probe items (Table 3). Individuals who first
used tobacco at 15 years or younger were significantly
more likely to endorse DLE. With respect to the num-
ber of cigarettes per day, individuals with heavy smoking
(more than 22 cigarettes per day) were more likely to
endorse DLE probe items. However, the pattern of find-
ings in Model 2 did not suggest a clear dose-response
relationship.
Association between cannabis use disorders and DLE
Table 4 shows the association between cannabis use dis-
orders and DLE. Over 4% of the Australian adult popu-
lation met criteria for lifetime cannabis use disorder.
Those with cannabis dependence disorder were signifi-
cantly more likely to endorse DLE. Individuals with (a)
age of first use 16 years or younger were three times
more likely to endorse DLE items. Compared to nonu-
sers, users with the youngest age of onset (16 years or
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probe items.
Association between alcohol use disorders and DLE
Table 5 shows the association between alcohol use dis-
orders and DLE. While 18% of the adult population had
lifetime alcohol use disorder, the pattern of association
between this exposure and DLE was less consistent
across the adjusted models and the exposure categories.
Concerning age of onset of these two diagnoses versus
DLE, those with early onset (17 years or less) were sig-
nificantly more likely to endorse DLE probe items, how-
ever inspection of the data did not suggest a consistent
dose-response across the age of onset categories.
Finally, we undertook several post-hoc analyses in order
to explore the robustness of the findings. We examined
Table 2 Descriptive statistics of delusional-like experiences (DLE), tobacco use, and cannabis and alcohol use disorders
(n = 8,773*)
Exposure Sample
Number (%)
Delusional-like experiences endorsement
No (%) Yes (%)
@
Total sample 8773 (100.00) 7997(91.53) 776 (8.47)
Everyday tobacco use 1539 (17.97) 1325 (15.64) 214 (13.01)
Weekly tobacco use 302 (4.04) 266 (3.56) 36 (14.72)
No tobacco use 6932 (77.98) 6406 (72.33) 526 (7.24)
Cannabis use disorder, Lifetime 339 (4.22) 287 (3.63) 52 (13.98)
No Cannabis use disorder 8434 (95.78) 7710 (87.89) 724 (8.23)
Cannabis dependence disorder, Lifetime 130 (1.74) 99 (1.31) 31 (24.65)
No Cannabis dependence disorder 8643 (98.26) 7898 (90.21) 745 (8.19)
Alcohol use disorder, Lifetime 1490 (18.31) 1333 (16.60) 157 (9.35)
No alcohol use disorder 7283 (81.69) 6664 (74.93) 619 (8.28)
Alcohol dependence disorder, Lifetime 329 (3.71) 249 (2.84) 80 (23.42)
No alcohol dependence disorder 8444 (96.29) 7748 (88.69) 249 (7.89)
*The sample excludes the item related to past history of schizophrenia ‘doctor ever told you that you have schizophrenia’; DLE (Screen items)
@ Percentages denote risk set
Table 3 Relationship between tobacco use, and delusional-like experiences (n = 8,773)
Any Delusional-like experiences
Screen items Probe items
A. Tobacco use
Count
(%)
Model 1
1
OR
4 (95% CI
5)
Model 2
2
OR
4 (95% CI
5)
Model 1
1
OR
4 (95% CI
5)
Model 2
2
OR
4 (95% CI
5)
Smoking
Everyday 1539 (17.97) 1.86 (1.43, 2.43)* 1.39 (1.07, 1.81)* 2.37 (1.65, 3.39)* 1.66 (1.13, 2.44)*
Weekly 302 (4.05) 1.73 (0.99, 3.02) 1.28 (0.67, 2.45) 2.98 (1.09, 8.19)* 2.12 (0.65, 6.91)
Never 6932 (77.98) Reference Reference Reference Reference
B. Age of start of smoking everyday
Very early start (Q1: 6-15 y) 517 (5.78) 2.26 (1.63, 3.13) 1.61 (1.09, 2.36) 2.84 (1.82, 4.45) 1.82 (1.11, 3.00)
Early start (Q2:16-17y) 352 (4.51) 1.77 (1.18, 2.66) 1.42 (0.92, 2.18) 2.45 (1.31, 4.59) 1.78 (0.89, 3.52)
Mid age start (Q3: 18-19y) 307 (3.56) 1.00 (0.59, 1.69) 0.79 (0.47, 1.36) 1.51 (0.69, 3.29) 1.19 (0.55, 2.61)
Late start (Q4: 20y+) 360 (4.10) 1.93 (1.19, 3.12) 1.56 (0.97, 2.51) 1.56 (0.83, 2.94) 1.13 (0.61, 2.12)
Not smoking at all 7234 (82.04) Reference Reference Reference Reference
C. Number of cigarettes or tobacco products per day
Very heavy smoker (Q1: 23-75) 325 (3.97) 2.19 (1.46, 3.28) 1.63 (1.06, 2.51) 2.35 (1.24, 4.44) 1.54 (0.77, 3.09)
Heavy smoker (Q2:16-22) 313 (3.24) 1.76 (1.07, 2.91) 1.25 (0.76, 2.07) 2.71 (1.60, 4.59) 1.77 (1.05, 2.99)
Light smoker (Q3: 11-15) 314 (3.80) 1.65 (1.03, 2.67) 1.33 (0.82, 2.15) 1.72 (0.74, 4.01) 1.25 (0.52, 3.03)
Very light smoker (Q4: < 10) 584 (6.94) 1.68 (1.13, 2.51) 1.32 (0.85, 2.05) 2.06 (1.24, 3.41) 1.52 (0.89, 2.57)
Not smoking at all 7234 (82.04) Reference Reference Reference Reference
1Model 1 = Adjusted for age and sex;
2Model 2 = Adjusted for age, sex, marital status, migrant status, employment status, educational status, any anxiety
disorders, any depressive disorders, physical disorders and ‘other’ harmful substance use/dependence (’other’ harmful substance use/dependence denotes all
other drug/alcohol use/dependence);
4OR = Odds Ratio,
5CI = 95% Confidence Interval; *significance: p < 0.01 (shown in bold)
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harmful use and dependence disorders for both cannabis
and alcohol were restricted to past year diagnoses (instead
of lifetime ever). The pattern of findings remained
unchanged (data not shown). We also examined the
association between alcohol use disorders versus DLE
when demographic variables such as migrant status,
employment status and educational status were removed
from Model 2. Again, the pattern of findings remained
essentially unchanged (data not shown).
Table 4 Relationship between lifetime cannabis use/dependence (meeting criteria for DSM-IV disorder) and delusional-
like experiences (n = 8,773)
Any Delusional-like experiences
Screen items Probe items
A. Lifetime cannabis use/dependence disorder
Count (%) Model 1
1
OR
4 (95% CI
5)
Model 2
2
OR
4 (95% CI
5)
Model 1
1
OR
4 (95% CI
5)
Model 2
2
OR
4 (95% CI
5)
Cannabis use disorder Cannabis dependence
disorder
339 (4.23)
130 (1.74)
1.73 (1.12, 2.66)*
3.53 (1.87, 6.66)*
1.13 (0.71, 1.82)
1.76 (1.00, 2.75)*
2.28 (1.27, 4.12)*
5.51 (2.75, 11.05)*
1.35 (0.73, 2.49)
2.39 (1.14, 4.99)*
B. Age of onset of cannabis use disorder
Very early onset (Q1: 12-16y) 131 (1.59) 3.15 (1.80, 5.49) 1.85 (1.00, 3.44) 5.51 (2.42, 12.58) 2.85 (1.18, 6.89)
Early onset (Q2:17-18y) 123 (1.79) 1.39 (0.69, 2.81) 1.03 (0.49, 2.15) 3.08 (1.22, 7.77) 2.17 (0.84, 5.59)
Middle onset (Q3: 19-20y) 89 (1.26) 1.77 (0.64, 4.95) 1.08 (0.41, 2.84) 1.24 (0.20, 7.66) 0.70 (0.11, 4.46)
Late onset (Q4: 21-50y) 101 (1.09) 3.38 (1.65, 6.94) 1.93 (0.92, 4.05) 3.47 (1.46, 8.24) 1.73 (0.62, 4.82)
No onset of use disorder 8329 (94.28) Reference Reference Reference Reference
C. Age of onset of cannabis dependence
Very early onset (Q1: 12-16y) 32 (0.38) 5.83 (2.09, 16.19) 4.38 (1.39, 13.79) 12.73 (3.73, 43.66) 9.41 (2.42, 36.49)
Early onset (Q2:17-19y) 37 (0.65) 1.18 (0.27, 5.09) 0.76 (0.16, 3.52) 1.86 (0.49, 7.00) 1.11 (0.28, 4.44)
Middle onset (Q3: 20-22y) 28 (0.28) 1.43 (0.37, 5.52) 0.67 (0.16, 2.81) - -
Late onset (Q4: 23-50y) 31 (0.41) 10.39 (354, 30.56) 4.97 (1.58, 15.64) 6.34 (2.28, 17.63) 2.41 (0.76, 7.63)
No onset 8645 (98.27) Reference Reference Reference Reference
1Model 1 = Adjusted for age, sex,
2Model 2 = Adjusted for age, sex, marital status, migrant status, employment status, educational status, any anxiety disorders,
any depressive disorders, physical disorders and ‘other’ substance harmful use/dependence (’other’ substance harmful use/dependence denotes all other drug or
alcohol use/dependence other than cannabis)
3OR = Odds Ratio,
4CI = 95% Confidence Interval; *significance: p < 0.01 (shown in bold) - No estimates because of
low sample size
Table 5 Relationship between lifetime alcohol use disorder and delusional-like experiences (n = 8,773)
Any Delusional-like experiences
Screen items Probe items
A. Lifetime alcohol use/dependence disorder
Count (%) Model 1
1
OR
4 (95% CI
5)
Model 2
2
OR
4 (95% CI
5)
Model 1
1
OR
4 (95% CI
5)
Model 2
2
OR
4 (95% CI
5)
Alcohol use disorder, lifetime
Alcohol dependence disorder, lifetime
1490 (18.31)
329 (3.71, 0.28)
1.18 (0.89, 1.56)
3.50 (2.33, 5.28)*
1.01 (0.76, 1.33)
1.85 (1.15, 2.97)*
1.41 (0.97, 2.03)
4.48 (2.39, 8.40)*
1.09 (0.72, 1.63)
1.93 (0.91, 4.07)
B. Age of onset of alcohol use disorder
Very early onset (Q1: 9-17y) 361 (4.49) 2.26 (1.48, 3.46) 1.54 (0.99, 2.39) 3.50 (1.79, 6.84) 2.06 (1.02, 4.18)
Early onset (Q2:18-19y) 487 (6.34) 1.03 (0.70, 1.50) 0.87 (0.59, 1.29) 1.40 (0.75, 2.61) 1.14 (0.59, 2.16)
Middle onset (Q3: 20-25y) 509 (6.34) 1.55 (1.09, 2.19) 1.19 (0.80, 1.78) 2.17 (1.35, 3.51) 1.53 (0.87, 2.67)
Late onset (Q4: 26-79y) 441 (4.58) 2.25 (1.45, 3.49) 1.53 (0.96, 2.42) 2.08 (1.01, 4.29) 1.26 (0.54, 2.95)
No onset of use disorder 6975 (78.26) Reference Reference Reference Reference
C. Age of onset of alcohol dependence disorder
Very early (Q1: 12-17 y) 66 (0.86) 3.63 (1.84, 7.17) 1.69 (0.82, 3.49) 8.73 (3.33, 22.91) 3.51 (1.29, 9.52)
Early (Q2:18-20y) 100 (1.07) 1.19 (0.66, 2.15) 0.71 (0.39, 1.29) 2.18 (0.84, 5.65) 1.14 (0.45, 2.82)
Middle (Q3: 21-29y) 75 (0.85) 4.45 (1.79, 11.05) 1.99 (0.79, 5.02) 3.23 (1.16, 8.99) 1.18 (0.36, 3.88)
Late (Q4: 30-79y) 83 (0.84) 7.12 (2.97, 17.09) 4.29 (1.24, 14.89) 5.51 (131, 23.27) 2.84 (0.46, 17.66)
No onset 8449 (96.39) Reference Reference Reference Reference
1Model 1 = Adjusted for age, sex,
2Model 2 = Adjusted for age, sex, marital status, migrant status, employment status, educational status, any anxiety disorders,
any depressive disorders, physical disorders and ‘other’ substance harmful use/dependence (’other’ substance use/dependence disorders denotes all other drug
use/dependence other than alcohol)
3OR = Odds Ratio,
4CI = 95% Confidence Interval; *significance: p < 0.01 (shown in bold)
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Using a large nationally representative sample, we inves-
tigated the association between DLE versus tobacco use,
and cannabis and alcohol use disorders. We found that
D L Ew e r em o r el i k e l yt ob ee n d o r s e db yt h o s ew i t h( a )
everyday tobacco use, or (b) smoking onset aged 15 years
or younger. In keeping with studies exploring the links
between cannabis use and psychotic disorders, we found
that DLE were significantly more common in those with
(a) cannabis dependence, or (b) onset of cannabis use 16
years or younger. The general pattern of association per-
sisted when adjusted for a wide range of potential con-
founding factors, including comorbid polysubstance use.
These main findings are congruent with previous study
results of a similar population sample in Australia [15].
In addition, the current study found that earlier age at
onset of tobacco use, and cannabis use disorders were
significantly associated with DLE. In contrast, the pattern
of association between alcohol use/dependence disorder
and DLE was less consistent when adjusted for the pre-
sence of other substance use disorders.
The association between DLE and tobacco use
We found several significant associations between
tobacco-related variables and DLE. For example, com-
pared to non-smokers, DLE endorsement was more
common in those (a) those who use tobacco every day
(b) those who start smoking earlier before the age of 15
years those who used either 16-22 or 23 or more cigar-
ettes per day. These associations remained significant
after controlling for a set of potential confounding fac-
tors related to DLE and smoking. The results are consis-
tent with several prospective studies in which tobacco
smoking was found to be associated with later psychotic
symptoms [18-20]. The mechanisms underlying this
association remains unclear. Mindful that observational
studies are vulnerable to residual confounding, the find-
ings raise several research questions suitable for future
study. It is possible that the association between tobac-
cos use and DLE may reflect an increased propensity of
young people with psychotic experiences to commence
tobacco use. This may be influenced by intrinsic factors
(eg., shared genes) that predispose people with psychotic
symptoms to initiate and maintenance of smoking beha-
viours [34]. It is also feasible that nicotine in cigarettes
could modulate mesolimbic dopamine neurotransmitter
systems [35,36], which may increase the vulnerability to
DLE in susceptible individuals. Animal studies also
show that nicotine promotes the release of other neuro-
transmitters including acetylecholine, endogeneous
opioid peptides, GABA, norepinephrine and serotonin
[37] which may influence the pathogenesis of psychotic
symptoms.
The association between DLE and cannabis use disorders
In addition to the significant association between DLE
and cannabis use disorders, individuals with onset of use
disorders aged 16 years or younger had increased odds
of endorsing DLEs. While numerous prospective studies
have found an independent effect of cannabis use on the
development of psychotic disorders [3,4,6,9], our find-
ings are congruent with recent evidence showing that
cannabis use at a younger age was associated with psy-
chotic experiences [17]. One possible explanation is that
early exposure to THC (an active ingredients of canna-
bis) during critical periods of brain maturation has an
impact on the development of several neurotransmitter
systems which may interfere crucial process of brain
development [38]. Recent evidence suggests that Delta
9-THC modulates mediotemporal and ventrostriatal
function that may impair verbal learning and provoke
acute psychosis [39,40]. While it is believed that Delta
9-THC may produce permanent changes in the central
nervous system [41], recent studies found a clear
improvement in outcome in those who stopped use can-
nabis after the first psychotic episode [42].
The association between DLE and alcohol use and use
disorders
In contrast to association between tobacco smoking or
cannabis use and DLE, the pattern of association
between alcohol use disorders and DLE was less consis-
tent when adjusted for the presence of other substance
use disorders. For example, alcohol dependence was sig-
nificantly associated with endorsement of screen items,
but not probe items. The lack of association with the
probe items may reflect lack of power, as these items
were less frequently endorsed. There was some evidence
that early onset of alcohol use and dependence disorders
were associated with DLE endorsement (most noticeably
for probe items). While those with comorbid schizo-
phrenia and alcohol use disorders have worse clinical
outcomes [43], alcohol use has not been identified as a
risk factor for psychosis. It is feasible that alcohol use
may contribute to an abnormal persistence of DLE (i.e.
while DLE endorsement usually decreases over age,
those who use alcohol may have persistent DLE). This
research question may be suitable for further scrutiny
within longitudinal prospective studies.
Limitations
The study had several limitations. Importantly, the study
was cross-sectional and it was not possible to establish
the direction of causality between DLEs and the mea-
sures of substance use (we do not have information on
the age-of-onset of the DLE). Using a prospective birth
cohort and a nested sibling-pair study, we have
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bis use and later DLE and hallucinations [4]. We hope
to explore the association between early alcohol and
tobacco use and psychosis-related outcomes in this pro-
spective cohort in future studies. With respect to the
outcome measure, there were no items for hallucina-
tions. However, previous studies have shown a strong
association between DLE and hallucinations in general
population samples [44-46]. Finally, because the data
were obtained from a household survey some population
groups such as homeless, people living in nursing home,
hostels etc were not surveyed. The study results may
not also be generalised in other countries because of
potential differences in cultures and socio-economic
structures.
Conclusion
Our study provides evidence that tobacco, alcohol and
cannabis use disorders are associated with an increased
risk of endorsing DLEs. The findings confirm previous
findings, and contribute to the emerging literature indi-
cating shared risk factors between DLE and psychotic
disorders [47,48], and suggest the need for continued
research on the potentially harmful effects of the sub-
stance use disorders on psychosis-related outcomes.
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